Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: The A-BRAVE trial.
暂无分享,去创建一个
M. Dieci | P. Schmid | P. Conte | V. Guarneri | C. Tondini | G. Bisagni | G. D. Salvo | M. De Laurentiis | G. D. De Salvo | M. Laurentiis | Giacomo Moratello